Published in Br J Cancer on July 05, 2004
A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun (2010) 0.97
Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma. PLoS One (2009) 0.81
Cancer/Testis Antigen PASD1 Silences the Circadian Clock. Mol Cell (2015) 0.81
An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immun (2013) 0.80
Evolutionary conservation of a molecular machinery for export and expression of mRNAs with retained introns. RNA (2015) 0.77
CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. Haematologica (2010) 0.75
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer. Biomark Cancer (2015) 0.75
Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas. J Cancer Res Clin Oncol (2009) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood (1997) 11.04
At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol (1987) 9.21
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 4.89
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev (1998) 3.79
NPAS2: a gas-responsive transcription factor. Science (2002) 3.54
Structure and function of transcriptional activation domains. Curr Opin Genet Dev (1995) 2.94
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood (1999) 1.66
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A (2001) 1.49
Eukaryotic circadian systems: cycles in common. Genes Cells (1999) 1.32
Identification and characterization of Bimgamma, a novel proapoptotic BH3-only splice variant of Bim. Cancer Res (2002) 1.20
The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. Proc Natl Acad Sci U S A (2000) 1.19
Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev (2002) 1.08
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci U S A (2001) 1.03
Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Biomarkers Prev (2001) 1.02
Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun (2003) 1.00
Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma (1999) 0.96
Alternative spliced transcripts as cancer markers. Dis Markers (2001) 0.96
Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer (2002) 0.95
Aryl hydrocarbon receptor-mediated cell cycle control. Prog Cell Cycle Res (2003) 0.94
Analysis of the antibody repertoire of lymphoma patients. Cancer Immunol Immunother (2002) 0.88
Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas. Clin Cancer Res (2003) 0.88
Serologic detection of diffuse large B-cell lymphoma-associated antigens. Int J Cancer (2004) 0.83
Does a gene in the Xq28 region increase the risk of non-Hodgkin's lymphomas? Working Group for the Epidemiology of Hematolymphopoietic Malignancies in Italy. Ann Oncol (1999) 0.80
Structural abnormalities of the X chromosome in non-Hodgkin's lymphoma. Leukemia (1993) 0.80
Retention of CD44 introns in bladder cancer: understanding the alternative splicing of pre-mRNA opens new insights into the pathogenesis of human cancers. J Pathol (1995) 0.78
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A (1997) 7.07
The PPARs: from orphan receptors to drug discovery. J Med Chem (2000) 5.29
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell (1999) 4.32
CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood (2000) 3.99
Symbolic anatomic knowledge representation in the Read Codes version 3: structure and application. J Am Med Inform Assoc (1997) 3.97
Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med (1983) 3.63
Selective inhibition of fibronectin-mediated cell adhesion by monoclonal antibodies to a cell-surface glycoprotein. Science (1985) 3.24
Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J Clin Pathol (1982) 2.69
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43
Immunohistological analysis of human mononuclear phagocytes and dendritic cells by using monoclonal antibodies. Lab Invest (1986) 2.42
ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood (1998) 2.41
Asthma and irreversible airflow obstruction. Thorax (1984) 2.30
Anatomical characterisation of surgical procedures in the Read Thesaurus. Proc AMIA Annu Fall Symp (1996) 2.15
The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther (2014) 2.07
Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol (1997) 2.04
Nomenclature of magnetic, incommensurate, composition-changed morphotropic, polytype, transient-structural and quasicrystalline phases undergoing phase transitions. II. Report of an IUCr Working Group on Phase Transition Nomenclature. Acta Crystallogr A (2001) 2.02
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood (1997) 1.83
A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood (1997) 1.82
Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol (2000) 1.75
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood (1999) 1.59
Raisin poisoning in a dog. Vet Rec (2003) 1.57
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood (1999) 1.54
An anthropological perspective on obesity. Ann N Y Acad Sci (1987) 1.52
A novel explosive process is required for the gamma-ray burst GRB 060614. Nature (2006) 1.50
Course and treatment of patients with both substance use and posttraumatic stress disorders. Addict Behav (1999) 1.48
Plasmacytoid T cells. Immunohistochemical evidence for their monocyte/macrophage origin. Am J Pathol (1988) 1.46
Expression and function of a putative cell surface receptor for fibronectin in hamster and human cell lines. J Cell Biol (1986) 1.46
Nuclear localization of the SCL/TAL1 basic helix-loop-helix protein is not dependent on the presence of the basic domain. Blood (1995) 1.42
Targeted phototherapy of plaque-type psoriasis using ultraviolet B-light-emitting diodes. Br J Dermatol (2010) 1.42
Idiopathic salivary gland enlargement (sialadenosis) in dogs: a microscopic study. J Small Anim Pract (2000) 1.41
Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood (1999) 1.35
Alignment of genetic maps and QTLs between inter- and intra-specific sorghum populations. Theor Appl Genet (2006) 1.34
MicroRNA expression in lymphocyte development and malignancy. Leukemia (2008) 1.30
FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia (2005) 1.23
Posttraumatic stress disorder and war-zone exposure as correlates of perceived health in female Vietnam War veterans. J Consult Clin Psychol (1994) 1.21
Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia (2006) 1.17
Ultrasonographic evaluation of the thickness of the small intestinal wall in dogs with inflammatory bowel disease. J Small Anim Pract (2005) 1.14
A geodemographic analysis of the Denplan patient population in the North West Region. Br Dent J (2000) 1.13
Bronchioloalveolar carcinoma arising in longstanding lung cysts. Thorax (1984) 1.12
The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells. Leukemia (2006) 1.11
The respiratory tract immune system in the pig. I. Distribution of immunoglobulin-containing cells in the respiratory tract mucosa. Vet Pathol (1976) 1.10
A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res (2000) 1.09
Prescribing patients out of hours. Br Dent J (2001) 1.06
The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol (1997) 1.06
Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia (2006) 1.04
Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood (2000) 1.03
A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal Biochem (1993) 1.03
Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood (1999) 1.03
Primary biliary cirrhosis after long-term practolol administration. Br Med J (1978) 1.02
FMIP controls the adipocyte lineage commitment of C2C12 cells by downmodulation of C/EBP alpha. Oncogene (2006) 1.00
Human meningitis from Streptococcus equi subsp. zooepidemicus acquired as zoonoses. Epidemiol Infect (2010) 1.00
Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry (1992) 0.99
Effects of polyamines, polyamine analogs, and inhibitors of protein synthesis on spermidine-spermine N1-acetyltransferase gene expression. Biochemistry (1996) 0.98
Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. Blood (1998) 0.98
Association between fibronectin receptor and the substratum: spare receptors for cell adhesion. Exp Cell Res (1987) 0.98
Exploring the ontology of surgical procedures in the Read Thesaurus. Methods Inf Med (1998) 0.98
The surface properties and antigen-presenting function of hepatic non-parenchymal cells. Clin Exp Immunol (1981) 0.98
Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest (2001) 0.97
CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood (1995) 0.97
Review article: Fc gamma receptors in the human placenta. Placenta (1982) 0.97
Partial purification of Rho (D) antigen from Rh positive and negative erythrocytes. Proc Natl Acad Sci U S A (1979) 0.96
Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia (2006) 0.95
Hypereosinophilic syndrome in a cat. Vet Rec (1993) 0.95
FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Ann Rheum Dis (2008) 0.95
A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. Immunology (1986) 0.95
t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood (1999) 0.94
Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol (1994) 0.94
Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Histopathology (2007) 0.94
Fibronectin receptors of human keratinocytes and their expression during cell culture. J Cell Biol (1987) 0.93
Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukoc Biol (1999) 0.93
Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol (1998) 0.92
Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol (1997) 0.92
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia (2012) 0.92
Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol (1998) 0.91
Clinical administration procedures in the Read Thesaurus: extending the ENV 1828 model to support regional terminology requirements. Proc AMIA Symp (1998) 0.91
Characterisation of the soluble fraction of human syncytiotrophoblast microvillous plasma membrane-associated proteins. J Reprod Immunol (1979) 0.91
Lymphocyte-specific protein 1: a specific marker of human leucocytes. Immunology (1999) 0.91
Cellular distribution of human leucocyte adhesion molecule ICAM-3. J Clin Pathol (1994) 0.91
Rethinking health, development, and malaria: historicizing a cultural model in international health. Med Anthropol (1997) 0.91
Clinical and pathological features of thoracic neoplasia in the horse. Equine Vet J (1993) 0.91
The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood (1999) 0.91
A monoclonal antibody recognizing the p150/95 leucocyte differentiation antigen. Immunology (1986) 0.91
Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia (2008) 0.91
Identification of Rho(D) antigen in polyacrylamide gels by an enzyme-linked immunoassay. Mol Immunol (1982) 0.89
HomeLog: long-term recording of infant temperature, respiratory and cardiac signals in the home environment. J Paediatr Child Health (1992) 0.89
Cell division and giant cell formation in Kupffer cell cultures. Clin Exp Immunol (1980) 0.88
African swine fever virus encodes a serine protein kinase which is packaged into virions. J Virol (1993) 0.88
Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res (2001) 0.88
Irreversible airflow obstruction. Evolution in asthma. Med J Aust (1985) 0.88
Apnoea detection: human performance and reliability of a computer algorithm. Acta Paediatr (1995) 0.87
Isotope effects and alternative substrate reactivities for tryptophan 2,3-dioxygenase. J Biol Chem (1993) 0.87
Application of the FICTION technique for the simultaneous detection of immunophenotype and chromosomal abnormalities in routinely fixed, paraffin wax embedded bone marrow trephines. J Clin Pathol (2005) 0.87
PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia (2006) 0.86